AmgenCHIX:AMGD 90 EV-to-EBIT is 20.97 as of Jul. 13, 2026, which is 26% above its 10-year median of 16.70. GuruFocus rates CHIX:AMGD with a GF Score™ of 90/100 and a GF Value™ of €325.97 (Modestly Undervalued). The stock has 8 warning signs investors should review. Among 688 Drug Manufacturers companies, Amgen ranks worse than 59.3% on this metric.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Amgen's Enterprise Value is €211,986 Mil.
Amgen's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 was €10,107 Mil. Therefore, Amgen's EV-to-EBIT for today is 20.97.
The historical rank and industry rank for Amgen's EV-to-EBIT or its related term are showing as below:
CHIX:AMGd'
s EV-to-EBIT Range Over the Past 10 Years
Min: 9.92 Med: 16.7 Max: 35.01
Current: 20.5
During the past 13 years, the highest EV-to-EBIT of Amgen was 35.01. The lowest was 9.92. And the median was 16.70.
CHIX:AMGd's EV-to-EBIT is ranked worse than 59.3% of 688
companies
in the Drug Manufacturers industry
Industry Median: 15.885
vs CHIX:AMGd: 20.50
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Amgen's Enterprise Value for the quarter that ended in Mar. 2026 was €213,495 Mil.
Amgen's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €10,107 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Amgen EV-to-EBIT Related Terms
Amgen EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Amgen's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CHIX:AMGD vs GILD, PFE, BMY: EV-to-EBIT Comparison
For the Drug Manufacturers - General subindustry, Amgen's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Amgen EV-to-EBIT vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Amgen's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Amgen's EV-to-EBIT falls into.
Amgen's current Enterprise Value is €211,986 Mil.
Amgen's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €10,107 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Amgen (CHIX:AMGD) has a EV-to-EBIT of 20.97 as of Jul. 13, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Amgen and its competitors. This is 26% above median its historical median of 16.70. Over the past decade, Amgen's EV-to-EBIT has ranged from 9.92 to 35.01. According to the industry distribution chart, Amgen ranks #408 out of 688 companies in the Drug Manufacturers industry, placing it in the top 59.3%.
Is Amgen's EV-to-EBIT too high?
Amgen's current EV-to-EBIT of 20.97 is 26% above median its 10-year median of 16.70. Over the past 10 years, this metric has ranged from a low of 9.92 to a high of 35.01. The Drug Manufacturers industry median EV-to-EBIT is 15.89. Amgen's value of 20.97 is 32% above this industry median. Based on the distribution chart, Amgen ranks #408 out of 688 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Amgen has a GF Score™ of 90/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Amgen's EV-to-EBIT compare to GILD and PFE?
According to the Drug Manufacturers industry distribution chart, Amgen ranks #408 out of 688 companies for EV-to-EBIT. This places Amgen in the lower half of its industry. The industry median EV-to-EBIT is 15.89. Amgen's value of 20.97 is 32% above this benchmark. Historically, Amgen's own EV-to-EBIT has ranged from 9.92 to 35.01 over the past decade. While the company's 10-year median is 16.70 vs. the industry median of 15.89, Amgen has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Drug Manufacturers company?
The median EV-to-EBIT among Drug Manufacturers companies is 15.89, based on 688 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Amgen's current EV-to-EBIT of 20.97 is 32% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Amgen and its competitors. For the Drug Manufacturers industry, the median EV-to-EBIT is 15.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Amgen's current EV-to-EBIT is 20.97, which is 26% above median its own 10-year median of 16.70. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Amgen stock overvalued right now?
Based on GuruFocus' analysis, Amgen (CHIX:AMGD) is currently considered Modestly Undervalued. The stock's GF Value™ is €325.97, compared to a current price of €285.00 — trading 12.6% below its estimated fair value. The current EV-to-EBIT is 20.97, which is 26% above median its 10-year median of 16.70 and 32% above the Drug Manufacturers industry median of 15.89. Amgen's overall GF Score™ is 90/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Amgen (CHIX:AMGD), the current EV-to-EBIT is 20.97 as of Jul. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Amgen (CHIX:AMGD) Overvalued in 2026?
Based on GuruFocus' analysis, Amgen stock appears to be undervalued.
The current stock price of €285.00 is trading 12.6% below its estimated GF Value™ of €325.97.
GuruFocus considers Amgen to be Modestly Undervalued.
Key valuation signals for CHIX:AMGD:
EV-to-EBIT: 20.97 (26% above median its 10-year median of 16.70)
GF Value™: €325.97 vs. price of €285.00 (12.6% below fair value)
Industry Position: 32% above the Drug Manufacturers median (#408 of 688)
No single metric tells the full story. See the CHIX:AMGD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
90GF Score
Get the complete analysis for CHIX:AMGD
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:AMGD has been successfully added to your 
